Twist Bioscience Corp (TWST)

$50.97

+2.23

(+4.58%)

Market is closed - opens 7 PM, 24 Jun 2024

Insights on Twist Bioscience Corp

  • Increasing Revenue

    Revenue is up for the last 6 quarters, 54.24M → 75.30M (in $), with an average increase of 6.3% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -43.00M → -45.49M (in $), with an average decrease of 5.8% per quarter

  • Vs TMO

    In the last 3 years, Twist Bioscience Corp has experienced a drawdown of -58.4%, however Thermo Fisher Scientific, Inc. resisted the overall trend and outperformed by 49.3%

Performance

  • $48.32
    $50.97
    $50.97
    downward going graph

    5.2%

    Downside

    Day's Volatility :5.2%

    Upside

    0.0%

    downward going graph
  • $14.42
    $55.26
    $50.97
    downward going graph

    71.71%

    Downside

    52 Weeks Volatility :73.91%

    Upside

    7.76%

    downward going graph

Returns

PeriodTwist Bioscience CorpSector (Health Care)Index (Russel 2000)
3 Months
48.9%
0.9%
0.0%
6 Months
32.01%
8.7%
0.0%
1 Year
189.27%
11.2%
0.0%
3 Years
-58.41%
17.3%
-24.2%

Highlights

Market Capitalization
2.8B
Book Value
$9.63
Earnings Per Share (EPS)
-3.36
Wall Street Target Price
45.9
Profit Margin
-69.24%
Operating Margin TTM
-64.92%
Return On Assets TTM
-15.63%
Return On Equity TTM
-30.4%
Revenue TTM
277.5M
Revenue Per Share TTM
4.83
Quarterly Revenue Growth YOY
25.1%
Gross Profit TTM
84.2M
EBITDA
-161.2M
Diluted Eps TTM
-3.36
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-3.01
EPS Estimate Next Year
-2.5
EPS Estimate Current Quarter
-0.82
EPS Estimate Next Quarter
-0.77

Analyst Recommendation

Buy
    81%Buy
    12%Hold
    6%Sell
Based on 16 Wall street analysts offering stock ratings for Twist Bioscience Corp(by analysts ranked 0 to 5 stars)
Based on 16 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
13
13
13
Hold
2
2
2
Sell
1
1
1

Analyst Forecast

What analysts predicted

Downside of 9.95%

Current $50.97
Target $45.90

Company Financials

FY18Y/Y Change
Revenue
25.4M
↑ 136.16%
Net Income
-71.2M
↑ 20.11%
Net Profit Margin
-280.16%
↑ 270.69%
FY19Y/Y Change
Revenue
54.4M
↑ 113.89%
Net Income
-107.7M
↑ 51.14%
Net Profit Margin
-197.98%
↑ 82.18%
FY20Y/Y Change
Revenue
90.1M
↑ 65.67%
Net Income
-139.9M
↑ 29.96%
Net Profit Margin
-155.31%
↑ 42.67%
FY21Y/Y Change
Revenue
132.3M
↑ 46.87%
Net Income
-152.1M
↑ 8.69%
Net Profit Margin
-114.94%
↑ 40.37%
FY22Y/Y Change
Revenue
203.6M
↑ 53.83%
Net Income
-217.9M
↑ 43.24%
Net Profit Margin
-107.02%
↑ 7.92%
FY23Y/Y Change
Revenue
245.1M
↑ 20.41%
Net Income
-204.6M
↓ 6.08%
Net Profit Margin
-83.48%
↑ 23.54%
Q4 FY22Q/Q Change
Revenue
54.2M
↓ 5.34%
Net Income
-41.8M
↓ 18.18%
Net Profit Margin
-77.1%
↑ 12.1%
Q1 FY23Q/Q Change
Revenue
60.2M
↑ 10.95%
Net Income
-59.2M
↑ 41.44%
Net Profit Margin
-98.3%
↓ 21.2%
Q2 FY23Q/Q Change
Revenue
63.7M
↑ 5.92%
Net Income
-57.4M
↓ 2.98%
Net Profit Margin
-90.05%
↑ 8.25%
Q3 FY23Q/Q Change
Revenue
66.9M
↑ 5.03%
Net Income
-46.2M
↓ 19.43%
Net Profit Margin
-69.08%
↑ 20.97%
Q4 FY23Q/Q Change
Revenue
71.5M
↑ 6.8%
Net Income
-43.0M
↓ 7.0%
Net Profit Margin
-60.15%
↑ 8.93%
Q1 FY24Q/Q Change
Revenue
75.3M
↑ 5.32%
Net Income
-45.5M
↑ 5.78%
Net Profit Margin
-60.41%
↓ 0.26%
FY18Y/Y Change
Total Assets
115.8M
↑ 35.18%
Total Liabilities
317.2M
↑ 44.84%
FY19Y/Y Change
Total Assets
187.0M
↑ 61.49%
Total Liabilities
34.9M
↓ 88.99%
FY20Y/Y Change
Total Assets
398.9M
↑ 113.31%
Total Liabilities
62.6M
↑ 79.37%
FY21Y/Y Change
Total Assets
702.1M
↑ 76.02%
Total Liabilities
121.3M
↑ 93.67%
FY22Y/Y Change
Total Assets
961.4M
↑ 36.93%
Total Liabilities
172.0M
↑ 41.82%
FY23Y/Y Change
Total Assets
776.4M
↓ 19.24%
Total Liabilities
153.0M
↓ 11.06%
Q4 FY22Q/Q Change
Total Assets
910.0M
↓ 5.35%
Total Liabilities
163.6M
↓ 4.85%
Q1 FY23Q/Q Change
Total Assets
853.9M
↓ 6.16%
Total Liabilities
150.0M
↓ 8.34%
Q2 FY23Q/Q Change
Total Assets
810.3M
↓ 5.1%
Total Liabilities
152.8M
↑ 1.86%
Q3 FY23Q/Q Change
Total Assets
776.4M
↓ 4.19%
Total Liabilities
153.0M
↑ 0.12%
Q4 FY23Q/Q Change
Total Assets
732.8M
↓ 5.61%
Total Liabilities
142.8M
↓ 6.67%
Q1 FY24Q/Q Change
Total Assets
702.8M
↓ 4.09%
Total Liabilities
142.7M
↓ 0.04%
FY18Y/Y Change
Operating Cash Flow
-66.2M
↑ 28.97%
Investing Cash Flow
27.3M
↓ 373.33%
Financing Cash Flow
88.8M
↑ 39.22%
FY19Y/Y Change
Operating Cash Flow
-87.9M
↑ 32.91%
Investing Cash Flow
-104.8M
↓ 483.84%
Financing Cash Flow
158.6M
↑ 78.53%
FY20Y/Y Change
Operating Cash Flow
-142.3M
↑ 61.77%
Investing Cash Flow
-114.7M
↑ 9.39%
Financing Cash Flow
303.7M
↑ 91.53%
FY21Y/Y Change
Operating Cash Flow
-112.2M
↓ 21.1%
Investing Cash Flow
156.2M
↓ 236.2%
Financing Cash Flow
329.2M
↑ 8.38%
FY22Y/Y Change
Operating Cash Flow
-124.4M
↑ 10.82%
Investing Cash Flow
-232.9M
↓ 249.17%
Financing Cash Flow
270.5M
↓ 17.82%
Q4 FY22Q/Q Change
Operating Cash Flow
-54.1M
↑ 4167.56%
Investing Cash Flow
-7.0M
↓ 350.49%
Financing Cash Flow
-395.0K
↓ 131.85%
Q1 FY23Q/Q Change
Operating Cash Flow
-44.3M
↓ 18.09%
Investing Cash Flow
41.2M
↓ 690.45%
Financing Cash Flow
1.5M
↓ 486.08%
Q2 FY23Q/Q Change
Operating Cash Flow
-23.4M
↓ 47.14%
Investing Cash Flow
18.7M
↓ 54.64%
Financing Cash Flow
-661.0K
↓ 143.34%

Technicals Summary

Sell

Neutral

Buy

Twist Bioscience Corp is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Twist Bioscience Corp
Twist Bioscience Corp
20.7%
32.01%
189.27%
-58.41%
73.07%
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
-4.02%
-10.84%
2.89%
-19.38%
80.26%
Agilent Technologies Inc.
Agilent Technologies Inc.
-11.56%
-4.69%
12.57%
-9.15%
82.18%
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
-3.33%
6.59%
8.15%
13.98%
91.03%
Danaher Corp.
Danaher Corp.
-2.98%
10.18%
7.18%
-4.63%
79.36%
Iqvia Holdings Inc.
Iqvia Holdings Inc.
-5.81%
-6.4%
1.14%
-10.23%
37.36%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Twist Bioscience Corp
Twist Bioscience Corp
NA
NA
NA
-3.01
-0.3
-0.16
NA
9.63
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
48.06
48.06
4.75
11.05
0.72
0.23
NA
18.93
Agilent Technologies Inc.
Agilent Technologies Inc.
31.97
31.97
2.7
5.23
0.21
0.08
0.01
21.31
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
35.72
35.72
2.81
21.72
0.14
0.05
0.0
119.24
Danaher Corp.
Danaher Corp.
46.58
46.58
3.13
7.61
0.08
0.04
0.0
72.16
Iqvia Holdings Inc.
Iqvia Holdings Inc.
29.5
29.5
1.33
11.08
0.22
0.05
NA
34.82
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Twist Bioscience Corp
Twist Bioscience Corp
Buy
$2.8B
73.07%
NA
-69.24%
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
Buy
$41.0B
80.26%
48.06
23.26%
Agilent Technologies Inc.
Agilent Technologies Inc.
Buy
$39.4B
82.18%
31.97
18.84%
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
Buy
$212.7B
91.03%
35.72
14.2%
Danaher Corp.
Danaher Corp.
Buy
$187.7B
79.36%
46.58
18.55%
Iqvia Holdings Inc.
Iqvia Holdings Inc.
Buy
$39.4B
37.36%
29.5
9.01%

Institutional Holdings

  • ARK Investment Management LLC

    11.93%
  • BlackRock Inc

    9.92%
  • Vanguard Group Inc

    9.38%
  • Artisan Partners Limited Partnership

    7.97%
  • JPMorgan Chase & Co

    6.21%
  • Sumitomo Mitsui Trust Holdings Inc

    6.10%

Corporate Announcements

  • Twist Bioscience Corp Earnings

    Twist Bioscience Corp’s price-to-earnings ratio stands at None

    Read More

Company Information

at twist bioscience, our expertise is synthetic dna. we have developed a proprietary semiconductor-based synthetic dna manufacturing process featuring a 10,000-well silicon platform capable of producing synthetic biology tools, such as oligonucleotides, genes, pathways, chassis and genomes. by synthesizing dna on silicon instead of on traditional 96-well plastic plates, our platform overcomes the current inefficiencies of synthetic dna production, and enables cost-effective, rapid, high-quality and high throughput synthetic gene production. the twist bioscience platform has the potential to greatly accelerate the development of personalized medicine, sustainable chemical production, improved agriculture production as well as new applications such as in vivo diagnostics, biodetection and data storage. for more information, please visit www.twistbioscience.com .

Organization
Twist Bioscience Corp
Employees
919
CEO
Dr. Emily Marine Leproust Ph.D.
Industry
Health Technology

FAQs